In a significant stride towards improving the diagnosis of endometriosis, two non-invasive tests have recently received approval in the UK, sparking interest from Canadian health officials. Ziwig, the biotech company behind one of these tests, the Endotest, is actively seeking local partners to facilitate access for Canadian patients. With endometriosis affecting nearly two million individuals across Canada, the potential introduction of these tests could drastically improve the diagnostic journey for many women suffering from this often debilitating condition.
The Tests: A Game Changer for Diagnosis
The UK approved both the Endotest and another test called EndoSure on July 7, 2023. These innovative diagnostic tools are designed to expedite the identification of endometriosis, a condition that currently affects at least one in ten women in Canada. Symptoms can vary widely, ranging from chronic pelvic pain and painful menstruation to infertility and gastrointestinal issues. Notably, the severity of symptoms does not always correlate with the extent of the disease, making accurate diagnosis essential.
A representative from Ziwig expressed optimism regarding the potential for these tests to become available in Canada, stating, “Our salivary diagnostic test is not yet commercially available in Canada, but we are hopeful that these discussions will progress over the coming months.” Meanwhile, EndoSure has not confirmed whether it plans to enter the Canadian market.
Current Regulatory Landscape in Canada
As it stands, Health Canada has yet to approve these tests for clinical use, placing the responsibility for healthcare services—including diagnostic testing—on provincial and territorial health authorities. As each region considers the implications of introducing these tests, Saskatchewan and the Northwest Territories have both expressed interest in integrating them into their healthcare systems, contingent upon Health Canada’s approval.
Saskatchewan’s Ministry of Health stated that it “will consider coverage of tests that are approved by Health Canada,” while the Northwest Territories’ government indicated that it is “interested in innovations that have the potential to improve the diagnosis and care of residents living with conditions such as endometriosis.”
British Columbia’s health ministry also acknowledged awareness of these new technologies and expressed support for their introduction, provided they meet safety, cost-effectiveness, and clinical efficacy criteria.
The Science Behind the Tests
The EndoSure test operates by measuring electrical signals in the gut, utilising sensor pads placed on the abdomen. Patients are required to fast beforehand and consume water during the test to ensure accurate readings of gut activity. Results are typically available within approximately 30 minutes, making it a rapid diagnostic option.
In contrast, the Endotest relies on a saliva sample to detect microRNAs—tiny biological markers associated with the presence of endometriosis. Dr. Paul Yong, a Canadian expert in endometriosis, described these tests as “a huge step” toward reducing the historically lengthy diagnostic delays, which can average five years in Canada.
Both tests have been approved for a three-year evaluation period in the UK, where early economic modelling suggests they may be cost-effective. The NHS has endorsed their implementation, highlighting their potential to revolutionise the way endometriosis is diagnosed and monitored.
The Need for Timely Diagnosis
Despite advancements in diagnostic technology, the path to an endometriosis diagnosis remains fraught with challenges. Many women report feeling unheard or dismissed by healthcare professionals, significantly delaying their treatment. Dr. Mathew Leonardi, an academic gynecologic surgeon, emphasised the importance of listening to patients’ experiences, stating, “If you truly listen to a patient, you can achieve the diagnosis by talking alone.”
The call for more attention to patients’ symptoms is echoed by Violeta Kondovski, President of Endometriosis Canada. She noted that early diagnosis could prevent young women from missing school or dropping out of sports, thereby positively impacting their mental and social well-being. “It would be so much faster,” she explained, highlighting the urgency of addressing this long-standing issue.
Why it Matters
The potential introduction of non-invasive diagnostic tests for endometriosis in Canada represents a critical opportunity to enhance women’s healthcare. By reducing diagnosis times and improving access to effective treatments, these tests could transform the lives of countless women. As advocacy for better recognition of endometriosis grows, it is imperative that the medical community listens to patients and prioritises timely, compassionate care. The development and approval of innovative diagnostic tools not only reflect advancements in medical science but also the ongoing commitment to improving the quality of life for those affected by this painful condition.